[Drug development in Japan from the viewpoints of global pharmaceutical companies]

[Article in Japanese]

Review

[Article in Japanese]

Taku Seriu. Rinsho Ketsueki. 2009 Jul.

. 2009 Jul;50(7):556-62.

No abstract available

Similar articles

Effective global drug development strategy for obtaining regulatory approval in Japan in the context of ethnicity-related drug response factors.
Ichimaru K, Toyoshima S, Uyama Y. Ichimaru K, et al. Clin Pharmacol Ther. 2010 Mar;87(3):362-6. doi: 10.1038/clpt.2009.285. Epub 2010 Jan 27. Clin Pharmacol Ther. 2010. PMID: 20107436 Review. No abstract available.
Drug development research: diabetes favored over cardiovascular disease?
Suckling K. Suckling K. Curr Opin Investig Drugs. 2009 Mar;10(3):217-9. Curr Opin Investig Drugs. 2009. PMID: 19333877 No abstract available.
[Contact and dialogue between drug companies and the global regulatory authorities throughout research and development phase].
Kock M, Thomsen MK. Kock M, et al. Ugeskr Laeger. 2003 Apr 14;165(16):1649-52. Ugeskr Laeger. 2003. PMID: 12756820 Review. Danish.
Re-engineering drug discovery and development.
FitzGerald GA. FitzGerald GA. LDI Issue Brief. 2011 Oct;17(2):1-4. LDI Issue Brief. 2011. PMID: 22049582
Overcoming the obstacles in the pharma/biotech industry: 2008 update.
Graul AI, Revel L, Rosa E, Cruces E. Graul AI, et al. Drug News Perspect. 2009 Jan-Feb;22(1):39-51. doi: 10.1358/dnp.2009.22.1.1303817. Drug News Perspect. 2009. PMID: 19209298